Equities

SoftOx Solutions AS

  • Add to watchlist
  • Add to portfolio
  • Add an alert

SoftOx Solutions AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)0.058
  • Today's Change-0.001 / -1.69%
  • Shares traded6.26m
  • 1 Year change+75.76%
  • Beta1.9476
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOx’s product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

  • Revenue in NOK (TTM)13.59m
  • Net income in NOK-3.00m
  • Incorporated2012
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Opsy Holding AB4.42m-20.03m92.51m7.00--55.91--20.91-20.83-20.830.63210.12160.294--7.632,064,500.00-133.11-117.68-201.35-142.11154.30---452.72-----216.840.463-------43.22------
Spago Nanomedical AB (publ)468.22k-28.45m93.92m7.00--2.85--200.59-0.0513-0.05130.00080.04650.0115--4.3962,428.57-69.64-30.44-81.41-32.48-----6,076.43-3,410.33---------77.135.0218.32------
Biosergen AB0.00-32.78m106.17m2.00--4.89-----13.74-13.740.008.630.00----0.00-152.65---191.42--------------0.00------29.00------
Coegin Pharma AB0.00-22.12m108.22m3.00--8.67-----0.7859-0.78590.000.46810.00----0.00-85.07-133.34-91.51-179.59------------0.00------15.00------
Active Biotech AB publ0.00-41.25m109.30m5.00--13.33-----0.0737-0.07370.000.00290.00----0.00-241.37-94.38-927.66-120.44-------3,355.24----0.0816------13.98------
Annexin Pharmaceuticals AB (publ)0.00-39.53m112.69m4.00--4.22-----5.98-5.980.003.530.00----0.00-150.00-137.53-190.93-169.50------------0.00------26.58------
Exact Therapeutics AS0.00-72.20m118.94m12.00--1.76-----1.40-1.400.001.070.00----0.00-108.82-43.50-168.39-50.76-----------20.180.0052-------8.27--1.47--
Alligator Bioscience AB45.26m-83.27m120.27m13.00------2.66-2.16-2.160.6369-0.05920.5013--9.35938,822.30-92.22-97.96---155.50-----183.96-569.04----1.33---0.585167.685.91------
Glycorex Transplantation AB (publ)42.79m-7.56m122.69m20.00--3.2148.672.87-0.0917-0.09170.51740.47190.74421.455.201,997,000.00-13.15-15.79-17.51-18.6681.6887.06-17.67-44.851.56-15.830.1599--17.35-0.529663.97------
Abera Bioscience AB0.00-1.56m124.75m5.00--4.15-----0.0872-0.08720.001.510.00----0.00-6.61-68.96-7.94-85.65------------0.00------93.42------
Biovica International AB10.57m-81.93m129.48m24.00--1.04--12.25-0.6375-0.63750.06840.42410.079912.714.46365,333.30-61.92-58.22-70.41-66.49-171.53-462.09-775.22-1,804.168.11--0.0239--18.2338.8329.80---47.26--
Alzinova AB219.64k-28.80m129.84m5.00--0.5924--591.13-0.2846-0.28460.00221.230.0015--0.325441,000.00-19.42-12.21-20.69-12.85-5,834.15---13,114.15-21,390.81---1,794.800.0062---88.89---24.71--19.48--
SoftOx Solutions AS13.59m-3.00m141.25m5.00--1.30175.3910.39-0.001-0.0010.00650.04450.123--30.132,717,798.00-2.72-50.91-3.22-67.07-----22.07-644.921.16-3.920.1212--13.3814.06-8.86------
ViroGates A/S7.65m-18.78m165.38m7.00--32.06--21.63-1.63-1.630.66090.36650.35680.97774.41504,300.00-87.63-54.92-131.36-63.1547.3372.98-245.63-215.481.58-16.130.6277---12.276.45-18.59------
SenzaGen AB62.01m-17.33m175.76m37.00--2.21--2.83-0.5483-0.54831.962.520.55775.476.631,702,294.00-15.59-20.91-18.89-25.1765.0967.10-27.95-71.432.73--0.0707--15.6984.1619.22---1.18--
NextCell Pharma AB11.72m-37.65m179.03m24.00--2.52--15.28-0.4414-0.44140.1330.5960.138451.234.68---44.48-34.95-49.25-37.53-155.37-266.34-321.31-427.089.92------2.5625.1316.25--36.88--
Data as of Feb 10 2026. Currency figures normalised to SoftOx Solutions AS's reporting currency: Norwegian Krone NOK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.